Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma

S. Brugnatelli; A. Riccardi; G. Ucci; O. Mora; L. Barbarano; N. Piva; L. Piccinini; C. Bergonzi; A. De Paoli; M. Di Stasi; E. Rinaldi; G. Trotti; M. Petrini; E. Ascari

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma

S. Brugnatelli, A. Riccardi, G. Ucci, O. Mora, L. Barbarano, N. Piva, L. Piccinini, C. Bergonzi, A. De Paoli, M. Di Stasi, E. Rinaldi, G. Trotti, M. Petrini, E. Ascari

Research output: Contribution to journal › Article › peer-review

Abstract

In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m^-2) and epirubicin (70 mg m^-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

Original language	English
Pages (from-to)	794-797
Number of pages	4
Journal	British Journal of Cancer
Volume	73
Issue number	6
Publication status	Published - 1996

Keywords

Advanced myeloma
Cyclophosphamide
Epirubicin
Outpatient therapy
Randomisation

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma'. Together they form a unique fingerprint.

Cite this

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. / Brugnatelli, S.; Riccardi, A.; Ucci, G.; Mora, O.; Barbarano, L.; Piva, N.; Piccinini, L.; Bergonzi, C.; De Paoli, A.; Di Stasi, M.; Rinaldi, E.; Trotti, G.; Petrini, M.; Ascari, E.

In: British Journal of Cancer, Vol. 73, No. 6, 1996, p. 794-797.

Research output: Contribution to journal › Article › peer-review

@article{f8ab4ba1b93d4004839dd8cd78efcfce,

title = "Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma",

abstract = "In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.",

keywords = "Advanced myeloma, Cyclophosphamide, Epirubicin, Outpatient therapy, Randomisation",

author = "S. Brugnatelli and A. Riccardi and G. Ucci and O. Mora and L. Barbarano and N. Piva and L. Piccinini and C. Bergonzi and {De Paoli}, A. and {Di Stasi}, M. and E. Rinaldi and G. Trotti and M. Petrini and E. Ascari",

year = "1996",

language = "English",

volume = "73",

pages = "794--797",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma

AU - Brugnatelli, S.

AU - Riccardi, A.

AU - Ucci, G.

AU - Mora, O.

AU - Barbarano, L.

AU - Piva, N.

AU - Piccinini, L.

AU - Bergonzi, C.

AU - De Paoli, A.

AU - Di Stasi, M.

AU - Rinaldi, E.

AU - Trotti, G.

AU - Petrini, M.

AU - Ascari, E.

PY - 1996

Y1 - 1996

N2 - In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

AB - In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

KW - Advanced myeloma

KW - Cyclophosphamide

KW - Epirubicin

KW - Outpatient therapy

KW - Randomisation

UR - http://www.scopus.com/inward/record.url?scp=9244257281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244257281&partnerID=8YFLogxK

M3 - Article

C2 - 8611382

AN - SCOPUS:9244257281

VL - 73

SP - 794

EP - 797

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -